Literature DB >> 25510275

Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications.

Giorgio Inghirami1, Wing C Chan, Stefano Pileri.   

Abstract

T-cell lymphoproliferative disorders are a heterogeneous group of neoplasms with distinct clinical-biological properties. The normal cellular counterpart of these processes has been postulated based on functional and immunophenotypic analyses. However, T lymphocytes have been proven to be remarkably capable of modulating their properties, adapting their function in relationship with multiple stimuli and to the microenvironment. This impressive plasticity is determined by the equilibrium among a pool of transcription factors and by DNA chromatin regulators. It is now proven that the acquisition of specific genomic defects leads to the enforcement/activation of distinct pathways, which ultimately alter the preferential activation of defined regulators, forcing the neoplastic cells to acquire features and phenotypes distant from their original fate. Thus, dissecting the landscape of the genetic defects and their functional consequences in T-cell neoplasms is critical not only to pinpoint the origin of these tumors but also to define innovative mechanisms to re-adjust an unbalanced state to which the tumor cells have become addicted and make them vulnerable to therapies and targetable by the immune system. In our review, we briefly describe the pathological and clinical aspects of the T-cell lymphoma subtypes as well as NK-cell lymphomas and then focus on the current understanding of their pathogenesis and the implications on diagnosis and treatment.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  T-cell lymphoma; cell of origin; mechanisms of transformation

Mesh:

Substances:

Year:  2015        PMID: 25510275     DOI: 10.1111/imr.12248

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  12 in total

Review 1.  Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies.

Authors:  Chan-Wang J Lio; Hiroshi Yuita; Anjana Rao
Journal:  Blood       Date:  2019-10-31       Impact factor: 22.113

2.  Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.

Authors:  Francesco Maura; Luca Agnelli; Daniel Leongamornlert; Niccolò Bolli; Wing C Chan; Anna Dodero; Cristiana Carniti; Tayla B Heavican; Alessio Pellegrinelli; Giancarlo Pruneri; Adam Butler; Shriram G Bhosle; Annalisa Chiappella; Alice Di Rocco; Pier Luigi Zinzani; Francesco Zaja; Roberto Piva; Giorgio Inghirami; Wenyi Wang; Teresa Palomero; Javeed Iqbal; Antonino Neri; Peter J Campbell; Paolo Corradini
Journal:  Am J Hematol       Date:  2019-03-19       Impact factor: 10.047

3.  When cancer and immunology meet.

Authors:  Martin Carroll
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

4.  Acute deletion of TET enzymes results in aneuploidy in mouse embryonic stem cells through decreased expression of Khdc3.

Authors:  Romain O Georges; Hugo Sepulveda; J Carlos Angel; Eric Johnson; Susan Palomino; Roberta B Nowak; Arshad Desai; Isaac F López-Moyado; Anjana Rao
Journal:  Nat Commun       Date:  2022-10-20       Impact factor: 17.694

Review 5.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

6.  The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Authors:  Andreas Engert; Carlo Balduini; Anneke Brand; Bertrand Coiffier; Catherine Cordonnier; Hartmut Döhner; Thom Duyvené de Wit; Sabine Eichinger; Willem Fibbe; Tony Green; Fleur de Haas; Achille Iolascon; Thierry Jaffredo; Francesco Rodeghiero; Gilles Salles; Jan Jacob Schuringa
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

7.  Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Authors:  Michela Boi; Maria Todaro; Valentina Vurchio; Shao Ning Yang; John Moon; Ivo Kwee; Andrea Rinaldi; Heng Pan; Ramona Crescenzo; Mangeng Cheng; Leandro Cerchietti; Olivier Elemento; Maria E Riveiro; Esteban Cvitkovic; Francesco Bertoni; Giorgio Inghirami
Journal:  Oncotarget       Date:  2016-11-29

8.  Expression of activating natural killer-cell receptors is a hallmark of the innate-like T-cell neoplasm in peripheral T-cell lymphomas.

Authors:  Yu Uemura; Yasushi Isobe; Akiko Uchida; Junko Asano; Yuji Nishio; Hirotaka Sakai; Masahiro Hoshikawa; Masayuki Takagi; Naoya Nakamura; Ikuo Miura
Journal:  Cancer Sci       Date:  2018-02-15       Impact factor: 6.716

Review 9.  Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas.

Authors:  Teresa Poggio; Justus Duyster; Anna L Illert
Journal:  Cancers (Basel)       Date:  2018-09-18       Impact factor: 6.639

10.  Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis.

Authors:  Kari Högstrand; Stephanie Darmanin; TachaZi Plym Forshell; Alf Grandien
Journal:  Oncotarget       Date:  2018-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.